As World Awaits Results From Remdesivir Trials, Pricing Questions Loom

April 9

Hydroxychloroquine and chloroquine are far from the only drugs being tested for their potential to treat COVID-19, the disease caused by the novel coronavirus that has ballooned into a pandemic.

Another potentially promising therapy is remdesivir, an experimental antiviral drug developed by California-based Gilead Sciences, Inc. Previously, it has been tested on patients infected with Ebola and two other coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).

0 Comments

Radar on Drug Benefits

Leslie Small

Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. As the managing editor of Health Plan Weekly and Radar on Drug Benefits, she writes and edits for both publications while overseeing a small team of reporters who also focus on the managed care sector. Before joining AIS Health, she was a senior editor for the e-newsletter Fierce Health Payer, and she started her career as a copy editor at multiple local newspapers. She graduated with a dual degree in journalism and political science from Penn State University.